NCT07401173 DeepComp for Prediction of Gastric Cancer Postoperative Complications (DeepComp-Prospective)
| NCT ID | NCT07401173 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Qun Zhao |
| Condition | Gastric Cancer (Diagnosis) |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2026-03-01 |
| Primary Completion | 2026-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2026-03-01 with a primary completion date of 2026-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Gastric cancer is a leading cause of cancer-related mortality, and radical surgery remains the primary treatment. However, postoperative complications are common and can significantly impact patient recovery and quality of life. Currently, doctors lack precise tools to accurately predict which patients are at high risk for developing severe complications before surgery. This study aims to validate a novel artificial intelligence (AI) model called "DeepComp." The DeepComp model integrates clinical data with advanced radiomic features derived from routine preoperative CT scans. Specifically, it analyzes both the tumor characteristics and the patient's body composition (including skeletal muscle and fat distribution) to assess physiological reserve. In this prospective, multicenter observational study, researchers will enroll patients scheduled for gastric cancer surgery across five medical centers. The DeepComp model will be used to predict the risk of moderate-to-severe postoperative complications (Clavien-Dindo grade II or higher). These predictions will then be compared with the actual clinical outcomes observed 30 days after surgery. The goal is to determine the accuracy and reliability of the DeepComp model in a real-world clinical setting, potentially providing a powerful tool for personalized surgical risk assessment.
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years. Histologically confirmed gastric adenocarcinoma. Scheduled for elective radical gastrectomy (open, laparoscopic, or robotic) with curative intent. Standard preoperative contrast-enhanced abdominal CT scans (venous phase) performed within 14 days prior to surgery. Willingness to sign informed consent. Exclusion Criteria: Emergency surgery due to perforation, obstruction, or massive bleeding. Intraoperative findings of distant metastasis (Stage IV) or unresectable disease preventing R0 resection. Concurrent or previous malignant tumors within the last 5 years (except gastric cancer). Pregnancy or lactation. Severe metallic artifacts on CT images preventing radiomic analysis.
Contact & Investigator
Qun Zhao
PRINCIPAL INVESTIGATOR
th
Frequently Asked Questions
Who can join the NCT07401173 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Gastric Cancer (Diagnosis). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07401173 currently recruiting?
Yes, NCT07401173 is actively recruiting participants. Contact the research team at ding_ping_an@hebmu.edu.cn for enrollment information.
Where is the NCT07401173 trial being conducted?
This trial is being conducted at Shijiazhuang, China.
Who is sponsoring the NCT07401173 clinical trial?
NCT07401173 is sponsored by Qun Zhao. The principal investigator is Qun Zhao at th. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.